Pharmacological Treatment of Alzheimer’s Dementia: A Review

  • Stevo Knežević
  • Nenad Bogdanovic
  • George Spilich
  • Darko Chudy


For most individuals suffering from dementia, the prognosis is bleak. A small percentage (about 10%) of patients who present with such a clinical picture have potentially reversible dementia, and about one-third of that group will be cured. For those individuals with a probable diagnosis of Alzheimer’s disease (AD), the disease progresses with variable speed despite our best efforts (Clarfield, 1988). In spite of the irreversible nature of the disease, some treatment or assistance can still be offered. Pharmacological treatment may have a palliative effect upon the patient while social services, counseling and similar activities aid the patient and their family to cope with AD. In that respect, dementia is an example of a disease whose treatment requires a holistic medical approach.


Nerve Growth Factor Cholinergic Neuron Senile Dementia Carbo Line Clinical Neuropharmacology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amaduccie L, SMID Group (1988): Phosphatydilserine in the treatment of Alzheimer’s disease: results of multicenter study. Psychopharmacol Bull 24: 130–134Google Scholar
  2. Ambrozi L, Danielczyk W (1988): Treatment of impaired cerebral function in psychogeriatric patients with memantine-results of a phase II: double-blind study. Pharmacopsychiatry 21:144–146CrossRefGoogle Scholar
  3. Ashford JW, Sherman KA, Kumar V (1989): Advances in Alzheimer therapy: Cholinesterase inhibitors. Neurobiology of Aging 10:99–105CrossRefGoogle Scholar
  4. Bartus RT (1990): Drugs to treat age-related neurodegenerative problems. The final frontier of medical science? Jour American Geriatrics Society 38:680–695Google Scholar
  5. Clarfield AM (1988): The reversible dementias: Do they reverse? Annals of Internal Medicine 109:479–486Google Scholar
  6. Christie JE, Shering A, Ferguson J, Glen AIM (1981): Physostigmine and areco-line: Effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50CrossRefGoogle Scholar
  7. Davies P (1991): Therapy for Alzheimer’s disease: choosing a target. Clinical Neuropharmacology (Suppl 1) 14:S24-S33Google Scholar
  8. Decombe R, Bentue-Ferrer D, Reyman JM, Allain H (1990): Nouvelles perspectives thérapeutiques dans la maladie D’Alzheimer. Médecine et Hygiène 48:1825–1832Google Scholar
  9. Eagger SA, Levy R, Sahakian BJ (1991): Tacrine in Alzheimer’s disease. Lancet 337:989–992CrossRefGoogle Scholar
  10. Gash DM (1987): Neuronal transplantation: potential therapy for Alzheimer’s disease. J Neural Transm (suppl) 24:301–308Google Scholar
  11. Gauthier S, Bouchard R, Lamontagne A, Bailey P et al. (1990): Tetrahydroamino-acridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. N Eng J Med 322:1272–1276CrossRefGoogle Scholar
  12. Hefti F, Hartikka J, Knusel B (1989): Function of neurotrophic factor in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiology of Aging 10:515–533CrossRefGoogle Scholar
  13. Hollander E, Mohs RC, Davis KL (1986): Cholinergic approaches to the treatment of Alzheimer’s disease. Br Med Bull 42:97–100Google Scholar
  14. Itil TM, Menon GN, Songar A, Itis KZ (1986): CNS pharmacology and clinical therapeutic effects of oxiracetam. Clin Neuropharmacology (Suppl 3), 9:S70–S72Google Scholar
  15. Knezevic S, Mubrin Z, Risberg J, Vucinic G, Spilich G, Gubarev N, Wannen-Macher W (1989): Pyritinol treatment of SDAT patients: Evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Int Clinical Psychopharmacology 4:25–38CrossRefGoogle Scholar
  16. Mobley WC, Nerve RL, Prusiner SB, McKinley MP (1988): Nerve growth factor induces gene expression for prion-and Alzheimer’s ß-amyloid proteins. Proc Natl Acad Sci USA 85:9811–9815CrossRefGoogle Scholar
  17. Mohr E, Schlegel J, Fabbrini G et al. (1989): Clonidin treatment of Alzheimer’s disease. Arch Neurol 46:376–378CrossRefGoogle Scholar
  18. Mouradian MM, Mohr E, Williams JA, Chase TN (1988): No response to high dose muscarinic agonist therapy in Alzheimer’s disease. Neurology 38:606–608Google Scholar
  19. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988): Intrevenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology 95:171–175CrossRefGoogle Scholar
  20. Orgogozo JM, Spiegel R (1987): Critical review of clinical trials in dementia II. Postgraduate Medical Journal 63:337–343CrossRefGoogle Scholar
  21. Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM (1988): Intraventricular bethanechol infusion for Alzheimer’s. Neurology 38:219–222Google Scholar
  22. Phelps CH, Gage FH, Growdon JH et al. (1989): Potential use of Nerve Growth Factor to treat Alzheimer’s disease. Neurobiology of Aging 10:205–207CrossRefGoogle Scholar
  23. Reifler BV, Teri L, Raskind M et al. (1989): Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry 146:45–49Google Scholar
  24. Roberts F, Lazareno S (1989): Cholinergic treatments for Alzheimer’s disease. Biochemical Society Transactions 17:76–79Google Scholar
  25. Robakis NK, Anderson JP, Refolo LM, Wallace W (1991): Expression of the Alzheimer amyloid precursor in brain tissue and effects of NGF and EGF on its metabolism. Clinical Neuropharmacology (Suppl 1) 14:S15-S23Google Scholar
  26. Sarter M, Schneider HH, Stephens DN (1988): Treatment strategies for senile dementia: antagonist β carbolines. TINS 11:13–17Google Scholar
  27. Sarter M, Stephens DN (1989): Disinhibitory properties of β carboline antagonists of benzodiazepine receptors: a possible therapeutic approach for senile dementia? Biochemical Society Transactions 17:81–83Google Scholar
  28. Schlegel J, Mohr E, Williams J, Mann U, Gearing M, Chase TN (1989): Guan-facine treatment of Alzheimer’s disease. Clinical Neuropharmacology 12: 124–128CrossRefGoogle Scholar
  29. Singh VK, Fudenberg HH (1988): Implications of immunomodulant therapy in Alzheimer’s disease. Prog Drug Research 32:21–42Google Scholar
  30. Spilich GJ, June L, Renner J (1992): Cigarette smoking and cognitive performance. British Journal of Addiction, in pressGoogle Scholar
  31. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986): Oral tetrahy-droaminoacridine in long term treatment of senile dementia, Alzheimer type. N Eng J Med 315:1241–1245CrossRefGoogle Scholar
  32. Tariot PN, Sunderland T, Cohen RM, Newhouse PA, Mueller EA, Murphy EL (1988): Tranylcipromine compared with L-deprenyl in Alzheimer’s disease. J Clin Psychopharmacology 8:23–27Google Scholar
  33. Tuszynski MH, Hoisang U, Amaral DG, Gage FH (1990): Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neuroscience 10:3604–3614Google Scholar
  34. Vandenabeele P, Fiers W (1991): Is amyloidogenesis during Alzheimer’s disease due to an IL-l-/IL-6-mediated “acute phase response” in the brain. Immunology Today 12:217–219CrossRefGoogle Scholar
  35. Waters C (1988): Cognitive Enhancing Agents: Current status in the treatment of Alzheimer’s disease. Can J Neurol Sci 15:249–256Google Scholar

Copyright information

© Birkhäuser Boston 1992

Authors and Affiliations

  • Stevo Knežević
  • Nenad Bogdanovic
  • George Spilich
  • Darko Chudy

There are no affiliations available

Personalised recommendations